In August, EDAP confirmed the completion of all follow-up visits in connection with its Ablatherm-HIFU ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer. The Company is on track to file its Premarket Approval (PMA) with the U.S. FDA in the fourth quarter of 2012.In June, EDAP's experts in HIFU technology presented their recent advances in the development of therapeutic focused ultrasound at the 12th International Symposium of Therapeutic Ultrasound (ISTU 2012) held in Germany. Top level technical presentations from the Company's partner INSERM, a French public research laboratory, addressed the successful evaluation of HIFU technology in targeting liver cancer. Other presentations related to HIFU as a therapy for prostate cancer, and included a poster that examined data from large cohorts of prostate cancer patients treated with the Ablatherm-HIFU over more than ten years, computed from a comprehensive clinical registry. The long-term results confirm EDAP as the most advanced player in the use of HIFU to address prostate cancer.
EDAP Reports Second Quarter 2012 Revenues Up 61%
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts